EGFR and neoplasm: Second, all of the included studies were retrospective in design, with insufficient data, such as therapy details, tumor stage, cut-off point, smoking history, patient age, or molecular tumor alterations (e.g., epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene, or anaplastic lymphoma kinase), and thus the results could not be further stratified with other potential confounding factors that can affect the major outcomes.